The Effect of Combination Chemotherapy with Carilizumab on Serum Tumor Markers and Its Anti Angiogenic Effect in Patients with Advanced NSCLC
CHEN Pengtao
RAO Hongyan
ZHANG Qianyong
QIU Wenbin
Abstract：Objective To study the effect of combination therapy with carilizumab on serum tumor marker levels and its anti angiogenic effect in patients with advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on 50 patients with advanced NSCLC who received treatment at Fuding Hospital from January 2020 to December 2023.According to the treatment plan,they were divided into a control group of 27 patients(receiving chemotherapy)and a combination group of 23 patients(receiving combination chemotherapy with carilizumab).The clinical efficacy,serum tumor markers,angiogenesis indicators,and adverse reactions between two groups of patients were compared.Results The objective response rate of the combined group was higher than that of the control group(P<0.05).The cytokeratin 19 fragment antigen 21-1,carcinoembryonic antigen,squamous cell carcinoma antigen,and carbohydrate antigen 125 in the combined group were lower than those in the control group(P<0.05).The vascular endothelial growth factor,matrix metalloproteinase-9,basic fibroblast growth factor,and platelet-derived growth factor in the combined group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of carilizumab and chemotherapy can effectively improve the treatment efficacy of advanced NSCLC,reduce tumor marker levels,inhibit tumor angiogenesis,and have good safety.
Keywords：Non-Small Cell Lung CancerKarelizumabChemotherapyTumor MarkersAngiogenesis
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 47-50 )